Shimla Online

DelveInsight Estimates a Diverse Kaposi Sarcoma Pipeline Comprising 5+ Companies Working in the Domain

 Breaking News
  • No posts were found

DelveInsight Estimates a Diverse Kaposi Sarcoma Pipeline Comprising 5+ Companies Working in the Domain

March 03
01:09 2023
DelveInsight Estimates a Diverse Kaposi Sarcoma Pipeline Comprising 5+ Companies Working in the Domain

DelveInsight’s, “Kaposi’s Sarcoma Pipeline Insight, 2023,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Kaposi’s Sarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


For Kaposi Sarcoma Emerging drugs, the Kaposi Sarcoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Kaposi Sarcoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.


In the Kaposi Sarcoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Kaposi Sarcoma clinical trials studies, Kaposi Sarcoma NDA approvals (if any), and product development activities comprising the technology, Kaposi Sarcoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.


Key takeaways from the Kaposi Sarcoma Pipeline Report


  • Over 5+ Kaposi Sarcoma companies are evaluating 5+ Kaposi Sarcoma pipeline therapies in various stages of development, and their anticipated acceptance in the Kaposi Sarcoma market would significantly increase market revenue.


  • The leading Kaposi Sarcoma Companies includes Vasgene Therapeutics, Bristol Myers Squibb, SkinDermic, Aphios, TTY Biopharm, NeoImmuneTech, Cello Therapeutics, and others.


  • Promising Kaposi Sarcoma Pipeline Therapies includes ABC294640, aldoxorubicin, Maraviroc, Alitretinoin, Semaxanib, valganciclovir, and others.


  • The Kaposi Sarcoma Companies and academics are working to assess challenges and seek opportunities that could influence Kaposi’s sarcoma R&D. The Kaposi Sarcoma pipeline therapies under development are focused on novel approaches to treat/improve Kaposi’s sarcoma.


Request a sample and discover the recent breakthroughs happening in the Kaposi Sarcoma Pipeline landscape @ Kaposi Sarcoma Pipeline Outlook Report


Kaposi Sarcoma Overview

Kaposi sarcoma (KS) is a cancer that develops from the cells that line lymph or blood vessels. It usually appears as tumors on the skin or on mucosal surfaces such as inside the mouth, but tumors can also develop in other parts of the body (including the lymph nodes, lungs, or digestive tract). The abnormal cells of Kaposi sarcoma cause purplish, reddish blue, or dark brown/black skin lesions (macules, nodules, plaques) on the legs and the face. These lesions may look bad, but they usually cause no symptoms. However, when the lesions are in the lungs, liver, or digestive tract, they may cause serious problems like gastrointestinal bleeding or trouble breathing.


Kaposi Sarcoma Emerging Drugs Profile


  • sEphB4-HAS: Vasgene Therapeutics


sEphB4-HSA functions as a decoy receptor for the membrane-bound ligand Ephrin-B2 (Efnb2) and interferes with the binding of Efnb2 to its native receptors, including EphB4 and EphA3. This may result in a reduction of angiogenesis and a reduction in cell growth of Efnb2 and/or EphB4 over-expressing tumor cells. Soluble EphB4-HSA inhibits the interaction between EphB4 receptor kinase and its cognate ligand EphrinB2 and bidirectional signaling. EphB4-EphrinB2 are expressed on venous and arterial endothelium and critically required for maturation of newly forming vessels. sEphB4 inhibits angiogenesis in response to various vascular growth promoting agents and thus has a broad and novel anti-angiogenic activity. EphB4 is also highly induced in many cancers and sEphB4 has direct tumor cell cytotoxicity. sEphB4-HSA thus may impact survival and quality of life of many cancer victims. The drug is currently being investigated in Phase II stage of development to treat Kaposi’s sarcoma.


For further information, refer to the detailed Kaposi Sarcoma Drugs Launch, Kaposi Sarcoma Developmental Activities, and Kaposi Sarcoma News, click here for Kaposi Sarcoma Ongoing Clinical Trial Analysis


Kaposi Sarcoma Pipeline



  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates


Route of Administration

  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal


Molecule Type

  • Oligonucleotide
  • Peptide
  • Small molecule


Kaposi Sarcoma Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for Kaposi’s sarcoma. The companies which have their Kaposi’s sarcoma drug candidates in the most advanced stage, i.e. phase II include, Vasgene Therapeutics.


Find out more about the Kaposi Sarcoma Pipeline Segmentation, Therapeutics Assessment, Kaposi Sarcoma Emerging Drugs @ Kaposi Sarcoma Treatment Landscape


Scope of the Kaposi Sarcoma Pipeline Report


  • Coverage- Global


  • Kaposi Sarcoma Companies- Vasgene Therapeutics, Bristol Myers Squibb, SkinDermic, Aphios, TTY Biopharm, NeoImmuneTech, Cello Therapeutics, and others.


  • Kaposi Sarcoma Pipeline Therapies– ABC294640, aldoxorubicin, Maraviroc, Alitretinoin, Semaxanib, valganciclovir, and others.


  • Kaposi Sarcoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration 


Dive deep into rich insights for drugs for Kaposi Sarcoma Pipeline Companies and Therapies, click here @ Kaposi Sarcoma Unmet Needs and Analyst Views


Table of Content

  1. Introduction
  2. Executive Summary
  3. Kaposi’s sarcoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Kaposi’s sarcoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug Name: Company Name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. sEphB4-HAS: Vasgene Therapeutics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. NT-I7: NeoImmuneTech
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. CE-003: Cello Therapeutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Kaposi’s sarcoma Key Companies
  21. Kaposi’s sarcoma Key Products
  22. Kaposi’s sarcoma- Unmet Needs
  23. Kaposi’s sarcoma- Market Drivers and Barriers
  24. Kaposi’s sarcoma- Future Perspectives and Conclusion
  25. Kaposi’s sarcoma Analyst Views
  26. Kaposi’s sarcoma Key Companies
  27. Appendix


Got Queries? Find out the related information on Kaposi Sarcoma Mergers and acquisitions, Kaposi Sarcoma Licensing Activities @ Kaposi Sarcoma Recent Trends, and Future Perspectives


About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States